Stocktoria
Veradermics, Inc MANE
Veradermics, Inc (MANE) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-16 | LifeSci Capital | Outperform (init) |
| 2026-06-02 | Needham | Buy (init) |
| 2026-05-18 | Citigroup | Buy (main) |
| 2026-04-22 | Leerink Partners | Outperform (main) |
| 2026-03-02 | Cantor Fitzgerald | Overweight (init) |
| 2026-03-02 | Citigroup | Buy (init) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.939 |
| Retained earnings / assets | -0.809 |
| EBIT / assets | -0.474 |
| Equity / liabilities | -13.217 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MANE | Veradermics, Inc | 2/9 | -13.54 | — | — |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About Veradermics, Inc
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
FAQ
Is MANE financially healthy?
Veradermics, Inc's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does MANE pay a dividend?
No, Veradermics, Inc does not currently pay a dividend.
What is the analyst price target for MANE?
The average Wall-Street price target for Veradermics, Inc is $132.80, about 21.8% above the recent price, from 5 analysts (consensus: strong buy).
Is MANE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Veradermics, Inc: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.